Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2014, Article ID 637027, 20 pages
http://dx.doi.org/10.1155/2014/637027
Review Article

Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective

1Department of Endocrinology and Metabolism, Shanghai 10th People’s Hospital, School of Medicine, Tongji University, No. 301 Middle Yanchang Road, Shanghai 200072, China
2Department of Neurology, Weill Cornell Medical College, New York, NY 10065, USA
3Department of Endocrinology and Metabolism, Nanjing Medical University, Nanjing, Jiangsu 210029, China

Received 14 May 2014; Revised 31 July 2014; Accepted 31 July 2014; Published 13 October 2014

Academic Editor: Liang-Jun Yan

Copyright © 2014 Aaron M. Gusdon et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Lazo, R. Hernaez, M. S. Eberhardt et al., “Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988–1994,” The American Journal of Epidemiology, vol. 178, no. 1, pp. 38–45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. K. L. Donnelly, C. I. Smith, S. J. Schwarzenberg, J. Jessurun, M. D. Boldt, and E. J. Parks, “Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease,” Journal of Clinical Investigation, vol. 115, no. 5, pp. 1343–1351, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. L. S. Szczepaniak, P. Nurenberg, D. Leonard et al., “Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 288, no. 2, pp. E462–E468, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. C. K. Argo and S. H. Caldwell, “Epidemiology and natural history of non-alcoholic steatohepatitis,” Clinics in Liver Disease, vol. 13, no. 4, pp. 511–531, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. J. D. Horton, J. L. Goldstein, and M. S. Brown, “SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver,” The Journal of Clinical Investigation, vol. 109, no. 9, pp. 1125–1131, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Uyeda and J. J. Repa, “Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis,” Cell Metabolism, vol. 4, no. 2, pp. 107–110, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. C. P. Day and O. F. W. James, “Hepatic steatosis: Innocent bystander or guilty party?” Hepatology, vol. 27, no. 6, pp. 1463–1466, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. C. P. Day and O. F. W. James, “Steatohepatitis: a tale of two “Hits”?” Gastroenterology, vol. 114, no. 4, pp. 842–845, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Cortez-Pinto, M. C. de Moura, and C. P. Day, “Non-alcoholic steatohepatitis: from cell biology to clinical practice,” Journal of Hepatology, vol. 44, no. 1, pp. 197–208, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Schuppan and J. M. Schattenberg, “Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches,” Journal of Gastroenterology and Hepatology, vol. 28, no. 1, pp. 68–76, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. D. O. Lazarin, E. L. Ishii-Iwamoto, N. S. Yamamoto et al., “Liver mitochondrial function and redox status in an experimental model of non-alcoholic fatty liver disease induced by monosodium l-glutamate in rats,” Experimental and Molecular Pathology, vol. 91, no. 3, pp. 687–694, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Hodson, S. E. McQuaid, S. M. Humphreys et al., “Greater dietary fat oxidation in obese compared with lean men: an adaptive mechanism to prevent liver fat accumulation?” The American Journal of Physiology—Endocrinology and Metabolism, vol. 299, no. 4, pp. E584–E592, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Iozzo, M. Bucci, A. Roivainen et al., “Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals,” Gastroenterology, vol. 139, no. 3, pp. e841–e846, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Ciapaite, N. M. van den Broek, H. Te Brinke et al., “Differential effects of short- and long-term high-fat diet feeding on hepatic fatty acid metabolism in rats,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1811, no. 7-8, pp. 441–451, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Iossa, L. Lionetti, M. P. Mollica et al., “Effect of high-fat feeding on metabolic efficiency and mitochondrial oxidative capacity in adult rats,” British Journal of Nutrition, vol. 90, no. 5, pp. 953–960, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. N. E. Sunny, S. Satapati, X. Fu et al., “Progressive adaptation of hepatic ketogenesis in mice fed a high-fat diet,” American Journal of Physiology: Endocrinology and Metabolism, vol. 298, no. 6, pp. E1226–E1235, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Garcia-Ruiz, C. Rodriguez-Juan, T. Diaz-Sanjuan et al., “Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice,” Hepatology, vol. 44, no. 3, pp. 581–591, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. Z. Li, S. Yang, H. Lin et al., “Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease,” Hepatology, vol. 37, no. 2, pp. 343–350, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. I. García-Ruiz, C. Rodríguez-Juan, T. Díaz-Sanjuán, M. Á. Martínez, T. Muñoz-Yagüe, and J. A. Solís-Herruzo, “Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice,” Hepatology, vol. 46, no. 2, pp. 414–423, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Chalasani, J. C. Gorski, M. S. Asghar et al., “Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis,” Hepatology, vol. 37, no. 3, pp. 544–550, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. A. J. Sanyal, C. Campbell-Sargent, F. Mirshahi et al., “Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities,” Gastroenterology, vol. 120, no. 5, pp. 1183–1192, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Miele, A. Grieco, A. Armuzzi et al., “Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test,” The American Journal of Gastroenterology, vol. 98, no. 10, pp. 2335–2336, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Dasarathy, Y. Yang, A. J. McCullough, S. Marczewski, C. Bennett, and S. C. Kalhan, “Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis,” European Journal of Gastroenterology and Hepatology, vol. 23, no. 5, pp. 382–388, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Romestaing, M.-A. Piquet, D. Letexier et al., “Mitochondrial adaptations to steatohepatitis induced by a methionine- and choline-deficient diet,” American Journal of Physiology: Endocrinology and Metabolism, vol. 294, no. 1, pp. E110–E119, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Vicentino, J. Constantin, A. Bracht, and N. S. Yamamoto, “Long-chain fatty acid uptake and oxidation in the perfused liver of Walker-256 tumour-bearing rats.,” Liver, vol. 22, no. 4, pp. 341–349, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Dasarathy, T. Kasumov, J. M. Edmison et al., “Glycine and urea kinetics in nonalcoholic steatohepatitis in human: effect of intralipid infusion,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 297, no. 3, pp. G567–G575, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Carmiel-Haggai, A. I. Cederbaum, and N. Nieto, “A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats,” The FASEB Journal, vol. 19, no. 1, pp. 136–138, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Jiang, M. Zhao, and W. An, “Increased hepatic apoptosis in high-fat diet-induced NASH in rats may be associated with downregulation of hepatic stimulator substance,” Journal of Molecular Medicine, vol. 89, no. 12, pp. 1207–1217, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Serviddio, F. Bellanti, R. Tamborra et al., “Alterations of hepatic ATP homeostasis and respiratory chain during development of non-alcoholic steatohepatitis in a rodent model,” European Journal of Clinical Investigation, vol. 38, no. 4, pp. 245–252, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Cortez-Pinto, J. Chatham, V. P. Chacko, C. Arnold, A. Rashid, and A. M. Diehl, “Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study,” Journal of the American Medical Association, vol. 282, no. 17, pp. 1659–1664, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. X. Jia, H. Naito, H. Yetti et al., “The modulation of hepatic adenosine triphosphate and inflammation by eicosapentaenoic acid during severe fibrotic progression in the SHRSP5/Dmcr rat model,” Life Sciences, vol. 90, no. 23-24, pp. 934–943, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. G. Serviddio, F. Bellanti, R. Tamborra et al., “Uncoupling protein-2 (UCP2) induces mitochondrial proton leak and increases susceptibility of non-alcoholic steatohepatitis (NASH) liver to ischaemia-reperfusion injury,” Gut, vol. 57, no. 7, pp. 957–965, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Jiang, H. Zhang, L.-Y. Dong, D. Wang, and W. An, “Increased hepatic UCP2 expression in rats with nonalcoholic steatohepatitis is associated with upregulation of Sp1 binding to its motif within the proximal promoter region,” Journal of Cellular Biochemistry, vol. 105, no. 1, pp. 277–289, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. I. García-Ruiz, D. Fernández-Moreira, P. Solís-Muñoz et al., “Mitochondrial complex i subunits are decreased in murine nonalcoholic fatty liver disease: implication of peroxynitrite,” Journal of Proteome Research, vol. 9, no. 5, pp. 2450–2459, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Wang, K. S. L. Lam, J. B. B. Lam et al., “Overexpression of angiopoietin-like protein 4 alters mitochondria activities and modulates methionine metabolic cycle in the liver tissues of db/db diabetic mice,” Molecular Endocrinology, vol. 21, no. 4, pp. 972–986, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Pérez-Carreras, P. Del Hoyo, M. A. Martín et al., “Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis,” Hepatology, vol. 38, no. 4, pp. 999–1007, 2003. View at Publisher · View at Google Scholar · View at Scopus
  37. K. D. Bruce, F. R. Cagampang, M. Argenton et al., “Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression,” Hepatology, vol. 50, no. 6, pp. 1796–1808, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Nadal-Casellas, E. Amengual-Cladera, A. M. Proenza, I. Lladó, and M. Gianotti, “Long-term high-fat-diet feeding impairs mitochondrial biogenesis in liver of male and female rats,” Cellular Physiology and Biochemistry, vol. 26, no. 3, pp. 291–302, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Teodoro, A. P. Rolo, P. J. Oliveira, and C. M. Palmeira, “Decreased ANT content in Zucker fatty rats: relevance for altered hepatic mitochondrial bioenergetics in steatosis,” FEBS Letters, vol. 580, no. 8, pp. 2153–2157, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Raffaella, B. Francesca, F. Italia, P. Marina, L. Giovanna, and I. Susanna, “Alterations in hepatic mitochondrial compartment in a model of obesity and insulin resistance,” Obesity, vol. 16, no. 5, pp. 958–964, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. S. K. Mantena, A. L. King, K. K. Andringa, H. B. Eccleston, and S. M. Bailey, “Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases,” Free Radical Biology and Medicine, vol. 44, no. 7, pp. 1259–1272, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. G. Vial, H. Dubouchaud, K. Couturier et al., “Effects of a high-fat diet on energy metabolism and ROS production in rat liver,” Journal of Hepatology, vol. 54, no. 2, pp. 348–356, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Zhang, O. Marcillat, C. Giulivi, L. Ernster, and K. J. A. Davies, “The oxidative inactivation of mitochondrial electron transport chain components and ATPase,” Journal of Biological Chemistry, vol. 265, no. 27, pp. 16330–16336, 1990. View at Google Scholar · View at Scopus
  44. H. A. Sadek, P. A. Szweda, and L. I. Szweda, “Modulation of mitochondrial complex I activity by reversible Ca2+ and NADH mediated superoxide anion dependent inhibition,” Biochemistry, vol. 43, no. 26, pp. 8494–8502, 2004. View at Publisher · View at Google Scholar · View at Scopus
  45. C. C. Kujoth, A. Hiona, T. D. Pugh et al., “Medicine: mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging,” Science, vol. 309, no. 5733, pp. 481–484, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. M. C. Carreras, M. C. Franco, J. G. Peralta, and J. J. Poderoso, “Nitric oxide, complex I, and the modulation of mitochondrial reactive species in biology and disease,” Molecular Aspects of Medicine, vol. 25, no. 1-2, pp. 125–139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. K. H. Moon, B. L. Hood, B. J. Kim et al., “Inactivation of oxidized and S-nitrosylated mitochondrial proteins in alcoholic fatty liver of rats,” Hepatology, vol. 44, no. 5, pp. 1218–1230, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. E. Aguirre, F. Rodríguez-Juárez, A. Bellelli, E. Gnaiger, and S. Cadenas, “Kinetic model of the inhibition of respiration by endogenous nitric oxide in intact cells,” Biochimica et Biophysica Acta, vol. 1797, no. 5, pp. 557–565, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. I. H. Bahcecioglu, M. Yalniz, H. Ataseven et al., “Levels of serum hyaluronic acid, TNF-α and IL-8 in patients with nonalcoholic steatohepatitis,” Hepato-Gastroenterology, vol. 52, no. 65, pp. 1549–1553, 2005. View at Google Scholar · View at Scopus
  50. N. Torer, S. Ozenirler, A. Yucel, N. Bukan, and O. Erdem, “Importance of cytokines, oxidative stress and expression of BCL-2 in the pathogenesis of non-alcoholic steatohepatitis,” Scandinavian Journal of Gastroenterology, vol. 42, no. 9, pp. 1095–1101, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Y. Kwon, Y. S. Jung, S. J. Kim, H. K. Park, J. H. Park, and Y. C. Kim, “Impaired sulfur-amino acid metabolism and oxidative stress in nonalcoholic fatty liver are alleviated by betaine supplementation in rats1,2,” The Journal of Nutrition, vol. 139, no. 1, pp. 63–68, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Nagakawa, G. M. Williams, Q. Zheng et al., “Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-α,” Hepatology, vol. 42, no. 1, pp. 208–215, 2005. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Gastaldelli, S. Harrison, R. Belfort-Aguiar et al., “Pioglitazone in the treatment of NASH: the role of adiponectin,” Alimentary Pharmacology and Therapeutics, vol. 32, no. 6, pp. 769–775, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Arsov, C. Z. Larter, C. J. Nolan et al., “Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice,” Biochemical and Biophysical Research Communications, vol. 342, no. 4, pp. 1152–1159, 2006. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Nannipieri, F. Cecchetti, M. Anselmino et al., “Pattern of expression of adiponectin receptors in human liver and its relation to nonalcoholic steatohepatitis,” Obesity Surgery, vol. 19, no. 4, pp. 467–474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Zhou, A. Xu, P. K. H. Tam et al., “Mitochondrial dysfunction contributes to the increased vulnerabilities of adiponectin knockout mice to liver injury,” Hepatology, vol. 48, no. 4, pp. 1087–1096, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Garcia-Ruiz, A. Colell, A. Morales, N. Kaplowitz, and J. C. Fernandez-Checa, “Role of oxidative stress generated from the mitochondrial electron transport chain and mitochondrial glutathione status in loss of mitochondrial function and activation of transcription factor nuclear factor-κB: studies with isolated mitochondria and rat hepatocytes,” Molecular Pharmacology, vol. 48, no. 5, pp. 825–834, 1995. View at Google Scholar · View at Scopus
  58. K. Hensley, Y. Kotake, H. Sang et al., “Dietary choline restriction causes complex I dysfunction and increased H2O2 generation in liver mitochondria,” Carcinogenesis, vol. 21, no. 5, pp. 983–989, 2000. View at Publisher · View at Google Scholar · View at Scopus
  59. M. P. Murphy, “How mitochondria produce reactive oxygen species,” The Biochemical Journal, vol. 417, no. 1, pp. 1–13, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. K. R. Pryde and J. Hirst, “Superoxide is produced by the reduced flavin in mitochondrial complex I: A single, unified mechanism that applies during both forward and reverse electron transfer,” Journal of Biological Chemistry, vol. 286, no. 20, pp. 18056–18065, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. C. L. Quinlan, A. A. Gerencser, J. R. Treberg, and M. D. Brand, “The mechanism of superoxide production by the antimycin-inhibited mitochondrial Q-cycle,” The Journal of Biological Chemistry, vol. 286, no. 36, pp. 31361–31372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Noguchi, J. D. Young, J. O. Aleman, M. E. Hansen, J. K. Kelleher, and G. Stephanopoulos, “Effect of anaplerotic fluxes and amino acid availability on hepatic lipoapoptosis,” Journal of Biological Chemistry, vol. 284, no. 48, pp. 33425–33436, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Valenzuela, A. Espinosa, D. Gonzalez-Manan, and et al, “N-3 long-chain polyunsaturated fatty acid supplementation significantly reduces liver oxidative stress in high fat induced steatosis,” PLoS ONE, vol. 7, no. 10, Article ID e46400, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. P. Puri, R. A. Baillie, M. M. Wiest et al., “A lipidomic analysis of nonalcoholic fatty liver disease,” Hepatology, vol. 46, no. 4, pp. 1081–1090, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. F. Caballero, A. Fernández, A. M. De Lacy, J. C. Fernández-Checa, J. Caballería, and C. García-Ruiz, “Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH,” Journal of Hepatology, vol. 50, no. 4, pp. 789–796, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. P. Simonen, A. Kotronen, M. Hallikainen et al., “Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity,” Journal of Hepatology, vol. 54, no. 1, pp. 153–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Marí, F. Caballero, A. Colell et al., “Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis,” Cell Metabolism, vol. 4, no. 3, pp. 185–198, 2006. View at Publisher · View at Google Scholar · View at Scopus
  68. G. P. Mannaerts, L. J. Debeer, J. Thomas, and P. J. de Schepper, “Mitochondrial and peroxisomal fatty acid oxidation in liver homogenates and isolated hepatocytes from control and clofibrate-treated rats,” Journal of Biological Chemistry, vol. 254, no. 11, pp. 4585–4595, 1979. View at Google Scholar · View at Scopus
  69. G. Robertson, I. Leclercq, and G. C. Farrell, “Nonalcoholic Steatosis and Steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 281, no. 5, pp. G1135–G1139, 2001. View at Google Scholar · View at Scopus
  70. S. K. Natarajan, C. E. Eapen, A. B. Pullimood, and K. A. Balasubramanian, “Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes,” Journal of Gastroenterology and Hepatology, vol. 21, no. 8, pp. 1240–1249, 2006. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Esterbauer, R. J. Schaur, and H. Zollner, “Chemistry and Biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes,” Free Radical Biology and Medicine, vol. 11, no. 1, pp. 81–128, 1991. View at Publisher · View at Google Scholar · View at Scopus
  72. G. Serviddio, F. Bellanti, G. Vendemiale, and E. Altomare, “Mitochondrial dysfunction in nonalcoholic steatohepatitis,” Expert Review of Gastroenterology and Hepatology, vol. 5, no. 2, pp. 233–244, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Seki, T. Kitada, T. Yamada, H. Sakaguchi, K. Nakatani, and K. Wakasa, “In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases,” Journal of Hepatology, vol. 37, no. 1, pp. 56–62, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. J. P. Infante and V. A. Huszagh, “Secondary carnitine deficiency and impaired docosahexaenoic (22:6n-3) acid synthesis: a common denominator in the pathophysiology of diseases of oxidative phosphorylation and β-oxidation,” FEBS Letters, vol. 468, no. 1, pp. 1–5, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Li, C. Romestaing, X. Han et al., “Cardiolipin remodeling by ALCAT1 links oxidative stress and mitochondrial dysfunction to obesity,” Cell Metabolism, vol. 12, no. 2, pp. 154–165, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. D. Pessayre and B. Fromenty, “NASH: a mitochondrial disease,” Journal of Hepatology, vol. 42, no. 6, pp. 928–940, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. A. E. Feldstein, “Novel insights into the pathophysiology of nonalcoholic fatty liver disease,” Seminars in Liver Disease, vol. 30, no. 4, pp. 391–401, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. H. Tilg, “The role of cytokines in non-alcoholic fatty liver disease,” Digestive Diseases, vol. 28, no. 1, pp. 179–185, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Bonnard, A. Durand, S. Peyrol et al., “Mitochondrial dysfunction results from oxidative stress in the skeletal muscle of diet-induced insulin-resistant mice,” Journal of Clinical Investigation, vol. 118, no. 2, pp. 789–800, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. T. Pacana and A. J. Sanyal, “Vitamin e and nonalcoholic fatty liver disease,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 15, no. 6, pp. 641–648, 2012. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Kugelmas, D. B. Hill, B. Vivian, L. Marsano, and C. J. McClain, “Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E,” Hepatology, vol. 38, no. 2, pp. 413–419, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. S. A. Harrison, S. Torgerson, P. Hayashi, J. Ward, and S. Schenker, “Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis,” The American Journal of Gastroenterology, vol. 98, no. 11, pp. 2485–2490, 2003. View at Publisher · View at Google Scholar · View at Scopus
  83. J. E. Lavine, “Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study,” Journal of Pediatrics, vol. 136, no. 6, pp. 734–738, 2000. View at Publisher · View at Google Scholar · View at Scopus
  84. A. J. Sanyal, N. Chalasani, K. V. Kowdley et al., “Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 362, no. 18, pp. 1675–1685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. E. R. Miller III, R. Pastor-Barriuso, D. Dalal, R. A. Riemersma, L. J. Appel, and E. Guallar, “Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality,” Annals of Internal Medicine, vol. 142, no. 1, pp. 37–46, 2005. View at Google Scholar · View at Scopus
  86. D. Berry, J. K. Wathen, and M. Newell, “Bayesian model averaging in meta-analysis: vitamin E supplementation and mortality,” Clinical Trials, vol. 6, no. 1, pp. 28–41, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association,” The American Journal of Gastroenterology, vol. 107, no. 6, pp. 811–826, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. S. K. Kim and Y. C. Kim, “Effects of betaine supplementation on hepatic metabolism of sulfur-containing amino acids in mice,” Journal of Hepatology, vol. 42, no. 6, pp. 907–913, 2005. View at Publisher · View at Google Scholar · View at Scopus
  89. M. F. Abdelmalek, S. O. Sanderson, P. Angulo et al., “Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial,” Hepatology, vol. 50, no. 6, pp. 1818–1826, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. C. P. de Oliveira, V. M. de Lima, F. I. Simplicio et al., “Prevention and reversion of nonalcoholic steatohepatitis in OB/OB mice by S-nitroso-N-acetylcysteine treatment,” Journal of the American College of Nutrition, vol. 27, no. 2, pp. 299–305, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. D. F. C. Mazo, M. G. de Oliveira, I. V. A. Pereira et al., “S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis,” Drug Design, Development and Therapy, vol. 7, pp. 553–563, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. J. T. Stefano, B. Cogliati, F. Santos et al., “S-Nitroso-N-acetylcysteine induces de-differentiation of activated hepatic stellate cells and promotes antifibrotic effects in vitro,” Nitric Oxide—Biology and Chemistry, vol. 25, no. 3, pp. 360–365, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. R. Vercelino, I. Crespo, G. F. P. de Souza et al., “S-nitroso-N-acetylcysteine attenuates liver fibrosis in cirrhotic rats,” Journal of Molecular Medicine, vol. 88, no. 4, pp. 401–411, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. G. E. Pamuk and A. Sonsuz, “N-acetylcysteine in the treatment of non-alcoholic steatohepatitis,” Journal of Gastroenterology and Hepatology (Australia), vol. 18, no. 10, pp. 1220–1221, 2003. View at Publisher · View at Google Scholar · View at Scopus
  95. M. Khoshbaten, A. Aliasgarzadeh, K. Masnadi et al., “N-acetylcysteine improves liver function in patients with non-alcoholic fatty liver disease,” Hepatitis Monthly, vol. 10, no. 1, pp. 12–16, 2010. View at Google Scholar · View at Scopus
  96. B. Catalgol, S. Batirel, Y. Taga, and N. K. Ozer, “Resveratrol: French paradox revisited,” Frontiers in Pharmacology, vol. 3, article 141, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. S. H. Jin, J. H. Yang, B. Y. Shin et al., “Resveratrol inhibits LXRα-dependent hepatic lipogenesis through novel antioxidant Sestrin2 gene induction,” Toxicology and Applied Pharmacology, vol. 271, no. 1, pp. 95–105, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Gómez-Zorita, A. Fernández-Quintela, M. T. MacArulla et al., “Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress,” British Journal of Nutrition, vol. 107, no. 2, pp. 202–210, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. L. Bujanda, E. Hijona, M. Larzabal et al., “Resveratrol inhibits nonalcoholic fatty liver disease in rats,” BMC Gastroenterology, vol. 8, article 40, 2008. View at Publisher · View at Google Scholar · View at Scopus
  100. G. L. Wang, Y. C. Fu, W. C. Xu, Y. Q. Feng, S. R. Fang, and X. H. Zhou, “Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway,” Biochemical and Biophysical Research Communications, vol. 380, no. 3, pp. 644–649, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. Y. Colak, O. Ozturk, E. Senates et al., “SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease,” Medical Science Monitor: International Medical Journal of Experimental and Clinical Research, vol. 17, no. 5, pp. HY5–HY9, 2011. View at Google Scholar
  102. J. Shang, L.-L. Chen, F.-X. Xiao, H. Sun, H.-C. Ding, and H. Xiao, “Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase,” Acta Pharmacologica Sinica, vol. 29, no. 6, pp. 698–706, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. J. Zheng and V. D. Ramirez, “Inhibition of mitochondrial proton F0F1-ATPase/ATP synthase by polyphenolic phytochemicals,” British Journal of Pharmacology, vol. 130, no. 5, pp. 1115–1123, 2000. View at Publisher · View at Google Scholar · View at Scopus
  104. R. Zini, C. Morin, A. Bertelli, A. A. E. Bertelli, and J.-P. Tillement, “Effects of resveratrol on the rat brain respiratory chain,” Drugs under Experimental and Clinical Research, vol. 25, no. 2-3, pp. 87–97, 1999. View at Google Scholar · View at Scopus
  105. C. Batandier, B. Guigas, D. Detaille et al., “The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin,” Journal of Bioenergetics and Biomembranes, vol. 38, no. 1, pp. 33–42, 2006. View at Publisher · View at Google Scholar · View at Scopus
  106. R. Moreno-Sánchez, L. Hernández-Esquivel, N. A. Rivero-Segura et al., “Reactive oxygen species are generated by the respiratory complex II—evidence for lack of contribution of the reverse electron flow in complex I,” The FEBS Journal, vol. 280, no. 3, pp. 927–938, 2013. View at Publisher · View at Google Scholar · View at Scopus
  107. G. Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, M. Zoli, and N. Melchionda, “Metformin in non-alcoholic steatohepatitis,” The Lancet, vol. 358, no. 9285, pp. 893–894, 2001. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Uygun, A. Kadayifci, A. T. Isik et al., “Metformin in the treatment of patients with non-alcoholic steatohepatitis,” Alimentary Pharmacology and Therapeutics, vol. 19, no. 5, pp. 537–544, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. S. Nair, A. M. Diehl, M. Wiseman, G. H. Farr Jr., and R. P. Perrillo, “Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial,” Alimentary Pharmacology and Therapeutics, vol. 20, no. 1, pp. 23–28, 2004. View at Publisher · View at Google Scholar · View at Scopus
  110. J. W. Haukeland, Z. Konopski, H. B. Eggesbø et al., “Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial,” Scandinavian Journal of Gastroenterology, vol. 44, no. 7, pp. 853–860, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. G. Musso, M. Cassader, F. Rosina, and R. Gambino, “Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials,” Diabetologia, vol. 55, no. 4, pp. 885–904, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. J. D. Browning and J. D. Horton, “Molecular mediators of hepatic steatosis and liver injury,” Journal of Clinical Investigation, vol. 114, no. 2, pp. 147–152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  113. F. Foufelle and P. Ferré, “New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c,” Biochemical Journal, vol. 366, no. 2, pp. 377–391, 2002. View at Publisher · View at Google Scholar · View at Scopus
  114. S. B. Biddinger, A. Hernandez-Ono, C. Rask-Madsen et al., “Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis,” Cell Metabolism, vol. 7, no. 2, pp. 125–134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. I. Shimomura, Y. Bashmakov, and J. D. Horton, “Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus,” Journal of Biological Chemistry, vol. 274, no. 42, pp. 30028–30032, 1999. View at Publisher · View at Google Scholar · View at Scopus
  116. L. Hebbard and J. George, “Animal models of nonalcoholic fatty liver disease,” Nature Reviews Gastroenterology and Hepatology, vol. 8, no. 1, pp. 34–44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  117. R. K. Semple, A. Sleigh, P. R. Murgatroyd et al., “Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis,” The Journal of Clinical Investigation, vol. 119, no. 2, pp. 315–322, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. D. E. Kelley, J. He, E. V. Menshikova, and V. B. Ritov, “Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes,” Diabetes, vol. 51, no. 10, pp. 2944–2950, 2002. View at Publisher · View at Google Scholar · View at Scopus
  119. J. D. McGarry, “Glucose-fatty acid interactions in health and disease,” The American Journal of Clinical Nutrition, vol. 67, no. 3, pp. 500S–504S, 1998. View at Google Scholar · View at Scopus
  120. K. Morino, K. F. Petersen, and G. I. Shulman, “Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction,” Diabetes, vol. 55, supplement 2, pp. S9–S15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  121. D. B. Savage, K. F. Petersen, and G. I. Shulman, “Disordered lipid metabolism and the pathogenesis of insulin resistance,” Physiological Reviews, vol. 87, no. 2, pp. 507–520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  122. R. Harmancey, C. R. Wilson, and H. Taegtmeyer, “Adaptation and maladaptation of the heart in obesity,” Hypertension, vol. 52, no. 2, pp. 181–187, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. W. L. Holland, J. T. Brozinick, L. P. Wang et al., “Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance,” Cell Metabolism, vol. 5, no. 3, pp. 167–179, 2007. View at Publisher · View at Google Scholar · View at Scopus
  124. C. Yu, Y. Chen, G. W. Cline et al., “Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle,” The Journal of Biological Chemistry, vol. 277, no. 52, pp. 50230–50236, 2002. View at Publisher · View at Google Scholar · View at Scopus
  125. C. A. Nagle, E. L. Klett, and R. A. Coleman, “Hepatic triacylglycerol accumulation and insulin resistance,” Journal of Lipid Research, vol. 50, pp. S74–S79, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. J. M. Brown, J. L. Betters, C. Lord et al., “CGI-58 knockdown in mice causes hepatic steatosis but prevents diet-induced obesity and glucose intolerance,” Journal of Lipid Research, vol. 51, no. 11, pp. 3306–3315, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. M. Monetti, M. C. Levin, M. J. Watt et al., “Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver,” Cell Metabolism, vol. 6, no. 1, pp. 69–78, 2007. View at Publisher · View at Google Scholar · View at Scopus
  128. C. Debard, D. Cozzone, N. Ricard et al., “Short-term activation of peroxysome proliferator-activated receptor β/δ increases fatty acid oxidation but does not restore insulin action in muscle cells from type 2 diabetic patients,” Journal of Molecular Medicine, vol. 84, no. 9, pp. 747–752, 2006. View at Publisher · View at Google Scholar · View at Scopus
  129. J. Cresser, A. Bonen, A. Chabowski et al., “Oral administration of a PPAR-δ agonist to rodents worsens, not improves, maximal insulin-stimulated glucose transport in skeletal muscle of different fibers,” The American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 299, no. 2, pp. R470–R479, 2010. View at Publisher · View at Google Scholar · View at Scopus
  130. J.-M. Ye, J. Tid-Ang, N. Turner et al., “PPARδ agonists have opposing effects on insulin resistance in high fat-fed rats and mice due to different metabolic responses in muscle,” British Journal of Pharmacology, vol. 163, no. 3, pp. 556–566, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. T. R. Koves, J. R. Ussher, R. C. Noland et al., “Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance,” Cell Metabolism, vol. 7, no. 1, pp. 45–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  132. D. M. Muoio, R. C. Noland, J.-P. Kovalik et al., “Muscle-specific deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility,” Cell Metabolism, vol. 15, no. 5, pp. 764–777, 2012. View at Publisher · View at Google Scholar · View at Scopus
  133. P. J. Randle, P. B. Garland, C. N. Hales, and E. A. Newsholme, “The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus,” The Lancet, vol. 281, no. 7285, pp. 785–789, 1963. View at Publisher · View at Google Scholar · View at Scopus
  134. L. Hue and H. Taegtmeyer, “The Randle cycle revisited: a new head for an old hat,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 297, no. 3, pp. E578–E591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  135. M. M. Bowker-Kinley, W. I. Davis, P. Wu, R. A. Harris, and K. M. Popov, “Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex,” The Biochemical Journal, vol. 329, part 1, pp. 191–196, 1998. View at Google Scholar · View at Scopus
  136. P. B. Garland, P. J. Randle, and E. A. Newsholme, “Citrate as an intermediary in the inhibition of phosphofructokinase in rat heart muscle by fatty acids, ketone bodies, pyruvate, diabetes and starvation,” Nature, vol. 200, no. 4902, pp. 169–170, 1963. View at Publisher · View at Google Scholar · View at Scopus
  137. P. B. Garland, E. A. Newsholme, and P. J. Randle, “Effect of fatty acids, ketone bodies, diabetes and starvation on pyruvate metabolism in rat heart and diaphragm muscle,” Nature, vol. 195, no. 4839, pp. 381–383, 1962. View at Publisher · View at Google Scholar · View at Scopus
  138. S. Nakamura, T. Takamura, N. Matsuzawa-Nagata et al., “Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria,” Journal of Biological Chemistry, vol. 284, no. 22, pp. 14809–14818, 2009. View at Publisher · View at Google Scholar · View at Scopus
  139. M. W. Ruddock, A. Stein, E. Landaker et al., “Saturated fatty acids inhibit hepatic insulin action by modulating insulin receptor expression and post-receptor signalling,” Journal of Biochemistry, vol. 144, no. 5, pp. 599–607, 2008. View at Publisher · View at Google Scholar · View at Scopus
  140. K. Loh, H. Deng, A. Fukushima et al., “Reactive oxygen species enhance insulin sensitivity,” Cell Metabolism, vol. 10, no. 4, pp. 260–272, 2009. View at Publisher · View at Google Scholar · View at Scopus
  141. K. L. Hoehn, A. B. Salmon, C. Hohnen-Behrens et al., “Insulin resistance is a cellular antioxidant defense mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 42, pp. 17787–17792, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Elchebly, P. Payette, E. Michaliszyn et al., “Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene,” Science, vol. 283, no. 5407, pp. 1544–1548, 1999. View at Publisher · View at Google Scholar · View at Scopus
  143. C. Yfanti, A. R. Nielsen, T. Åkerström et al., “Effect of antioxidant supplementation on insulin sensitivity in response to endurance exercise training,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 300, no. 5, pp. E761–E770, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. S. F. Praet and L. J. van Loon, “Exercise therapy in Type 2 diabetes,” Acta Diabetologica, vol. 46, no. 4, pp. 263–278, 2009. View at Publisher · View at Google Scholar · View at Scopus
  145. Z. Radak, Z. Zhao, E. Koltai, H. Ohno, and M. Atalay, “Oxygen consumption and usage during physical exercise: the balance between oxidative stress and ROS-dependent adaptive signaling,” Antioxidants and Redox Signaling, vol. 18, no. 10, pp. 1208–1246, 2013. View at Publisher · View at Google Scholar · View at Scopus
  146. V. A. Lira, C. R. Benton, Z. Yan, and A. Bonen, “PGC-1α regulation by exercise training and its influences on muscle function and insulin sensitivity,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 299, no. 2, pp. E145–E161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  147. T. T. Peternelj and J. S. Coombes, “Antioxidant supplementation during exercise training: beneficial or detrimental?” Sports Medicine, vol. 41, no. 12, pp. 1043–1069, 2011. View at Publisher · View at Google Scholar · View at Scopus
  148. C. V. Montfort, N. Matias, A. Fernandez et al., “Mitochondrial GSH determines the toxic or therapeutic potential of superoxide scavenging in steatohepatitis,” Journal of Hepatology, vol. 57, no. 4, pp. 852–859, 2012. View at Publisher · View at Google Scholar · View at Scopus
  149. M. P. Mollica, L. Lionetti, M. Moreno et al., “3,5-diiodo-l-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet,” Journal of Hepatology, vol. 51, no. 2, pp. 363–370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  150. M. Stefanovic-Racic, G. Perdomo, B. S. Mantell, I. J. Sipula, N. F. Brown, and R. M. O'Doherty, “A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 294, no. 5, pp. E969–E977, 2008. View at Publisher · View at Google Scholar · View at Scopus
  151. S. Timmers, M. Nabben, M. Bosma et al., “Augmenting muscle diacylglycerol and triacylglycerol content by blocking fatty acid oxidation does not impede insulin sensitivity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 29, pp. 11711–11716, 2012. View at Publisher · View at Google Scholar · View at Scopus
  152. W. Keung, J. R. Ussher, J. S. Jaswal et al., “Inhibition of carnitine palmitoyltransferase-1 activity alleviates insulin resistance in diet-induced obese mice,” Diabetes, vol. 62, no. 3, pp. 711–720, 2013. View at Publisher · View at Google Scholar · View at Scopus
  153. R. Conti, E. Mannucci, P. Pessotto et al., “Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis,” Diabetes, vol. 60, no. 2, pp. 644–651, 2011. View at Publisher · View at Google Scholar · View at Scopus
  154. N. B. Ruderman, D. Carling, M. Prentki, and J. M. Cacicedo, “AMPK, insulin resistance, and the metabolic syndrome,” The Journal of Clinical Investigation, vol. 123, no. 7, pp. 2764–2772, 2013. View at Publisher · View at Google Scholar · View at Scopus
  155. B. Xiao, M. J. Sanders, E. Underwood et al., “Structure of mammalian AMPK and its regulation by ADP,” Nature, vol. 472, pp. 230–233, 2011. View at Publisher · View at Google Scholar · View at Scopus
  156. J. S. Oakhill, R. Steel, Z.-P. Chen et al., “AMPK is a direct adenylate charge-regulated protein kinase,” Science, vol. 332, no. 6036, pp. 1433–1435, 2011. View at Publisher · View at Google Scholar · View at Scopus
  157. M. J. Sanders, Z. S. Ali, B. D. Hegarty, R. Heath, M. A. Snowden, and D. Carling, “Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family,” The Journal of Biological Chemistry, vol. 282, no. 45, pp. 32539–32548, 2007. View at Publisher · View at Google Scholar · View at Scopus
  158. N. Stahmann, A. Woods, D. Carling, and R. Heller, “Thrombin activates AMP-activated protein kinase in endothelial cells via a pathway involving Ca2+/calmodulin-dependent protein kinase kinase β,” Molecular and Cellular Biology, vol. 26, no. 16, pp. 5933–5945, 2006. View at Publisher · View at Google Scholar · View at Scopus
  159. L. Racioppi and A. R. Means, “Calcium/calmodulin-dependent protein kinase kinase 2: roles in signaling and pathophysiology,” Journal of Biological Chemistry, vol. 287, no. 38, pp. 31658–31665, 2012. View at Publisher · View at Google Scholar · View at Scopus
  160. D. G. Hardie, “AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy,” Nature Reviews Molecular Cell Biology, vol. 8, no. 10, pp. 774–785, 2007. View at Publisher · View at Google Scholar · View at Scopus
  161. L. Hue and M. H. Rider, “The AMP-activated protein kinase: more than an energy sensor,” Essays in Biochemistry, vol. 43, pp. 121–137, 2007. View at Publisher · View at Google Scholar · View at Scopus
  162. D. B. Savage, S. C. Cheol, V. T. Samuel et al., “Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2,” The Journal of Clinical Investigation, vol. 116, no. 3, pp. 817–824, 2006. View at Publisher · View at Google Scholar · View at Scopus
  163. D. Carling, V. A. Zammit, and D. G. Hardie, “A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis,” The FEBS Letters, vol. 223, no. 2, pp. 217–222, 1987. View at Publisher · View at Google Scholar · View at Scopus
  164. C. A. Carlson and K. H. Kim, “Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation,” The Journal of Biological Chemistry, vol. 248, no. 1, pp. 378–380, 1973. View at Google Scholar · View at Scopus
  165. M. D. Fullerton, S. Galic, K. Marcinko et al., “Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin,” Nature Medicine, vol. 19, no. 12, pp. 1649–1654, 2013. View at Publisher · View at Google Scholar · View at Scopus
  166. G. W. Goodwin, C. S. Taylor, and H. Taegtmeyer, “Regulation of energy metabolism of the heart during acute increase in heart work,” The Journal of Biological Chemistry, vol. 273, no. 45, pp. 29530–29539, 1998. View at Publisher · View at Google Scholar · View at Scopus
  167. G. W. Goodwin and H. Taegtmeyer, “Improved energy homeostasis of the heart in the metabolic state of exercise,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 279, no. 4, pp. H1490–H1501, 2000. View at Google Scholar · View at Scopus
  168. J. R. B. Dyck, N. Kudo, A. J. Barr, S. P. Davies, D. G. Hardie, and G. D. Lopaschuk, “Phosphorylation control of cardiac acetyl-CoA carboxylase by cAMP-dependent protein kinase and 5'-AMP activated protein kinase,” European Journal of Biochemistry, vol. 262, no. 1, pp. 184–190, 1999. View at Publisher · View at Google Scholar · View at Scopus
  169. A.-S. Marsin, L. Bertrand, M. H. Rider et al., “Phosphorylation and activation of heart PFK-2 by AMPK has a role in the stimulation of glycolysis during ischaemia,” Current Biology, vol. 10, no. 20, pp. 1247–1255, 2000. View at Publisher · View at Google Scholar · View at Scopus
  170. J. T. Treebak, S. Glund, A. Deshmukh et al., “AMPK-mediated AS160 phosphorylation in skeletal muscle is dependent on AMPK catalytic and regulatory subunits,” Diabetes, vol. 55, no. 7, pp. 2051–2058, 2006. View at Publisher · View at Google Scholar · View at Scopus
  171. G. F. Merrill, E. J. Kurth, D. G. Hardie, and W. W. Winder, “AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle,” The American Journal of Physiology: Endocrinology and Metabolism, vol. 273, no. 6, pp. E1107–E1112, 1997. View at Google Scholar · View at Scopus
  172. R. R. Russell III, R. Bergeron, G. I. Shulman, and L. H. Young, “Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 277, no. 2, pp. H643–H649, 1999. View at Google Scholar · View at Scopus
  173. T. Tanaka, F. Sue, and H. Morimura, “Feed-forward activation and feed-back inhibition of pyruvate kinase type L of rat liver,” Biochemical and Biophysical Research Communications, vol. 29, no. 3, pp. 444–449, 1967. View at Publisher · View at Google Scholar · View at Scopus
  174. S. I. Taylor, C. Mukherjee, and R. L. Jungas, “Regulation of pyruvate dehydrogenase in isolated rat liver mitochondria. Effects of octanoate, oxidation reduction state, and adenosine triphosphate to adenosine diphosphate ratio,” Journal of Biological Chemistry, vol. 250, no. 6, pp. 2028–2035, 1975. View at Google Scholar · View at Scopus
  175. E. Van Schaftingen and H. G. Hers, “Inhibition of fructose-1,6-bisphosphatase by fructose 2,6-biphosphate,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 5, pp. 2861–2863, 1981. View at Publisher · View at Google Scholar · View at Scopus
  176. C. J. Bailey and K. J. Mynett, “Insulin requirement for the antihyperglycaemic effect of metformin,” British Journal of Pharmacology, vol. 111, no. 3, pp. 793–796, 1994. View at Publisher · View at Google Scholar · View at Scopus
  177. C. J. Bailey and R. C. Turner, “Metformin,” The New England Journal of Medicine, vol. 334, no. 9, pp. 574–579, 1996. View at Publisher · View at Google Scholar · View at Scopus
  178. M. A. Gomez-Samano, A. Gulias-Herrero, D. Cuevas-Ramos, and et al, “Metformin and improvement of the hepatic insulin resistance index independent of anthropometric changes,” Endocrine Practice, vol. 18, no. 1, pp. 8–16, 2012. View at Publisher · View at Google Scholar · View at Scopus
  179. G. Zhou, R. Myers, Y. Li et al., “Role of AMP-activated protein kinase in mechanism of metformin action,” The Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167–1174, 2001. View at Publisher · View at Google Scholar · View at Scopus
  180. M. Foretz, S. Hébrard, J. Leclerc et al., “Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state,” The Journal of Clinical Investigation, vol. 120, no. 7, pp. 2355–2369, 2010. View at Publisher · View at Google Scholar · View at Scopus
  181. M.-Y. El-Mir, V. Nogueira, E. Fontaine, N. Avéret, M. Rigoulet, and X. Leverve, “Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I,” The Journal of Biological Chemistry, vol. 275, no. 1, pp. 223–228, 2000. View at Publisher · View at Google Scholar · View at Scopus
  182. M. R. Owen, E. Doran, and A. P. Halestrap, “Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain,” Biochemical Journal, vol. 348, no. 3, pp. 607–614, 2000. View at Publisher · View at Google Scholar · View at Scopus
  183. Z. Drahota, E. Palenickova, R. Endlicher et al., “Biguanides inhibit complex I, II and IV of rat liver mitochondria and modify their functional properties,” Physiological Research, vol. 63, no. 1, pp. 1–11, 2014. View at Google Scholar · View at Scopus
  184. G. Schaefer, “Some new aspects on the interaction of hypoglycemia producing biguanides with biological membranes,” Biochemical Pharmacology, vol. 25, no. 18, pp. 2015–2024, 1976. View at Publisher · View at Google Scholar · View at Scopus
  185. R. A. Miller, Q. Chu, J. Xie, M. Foretz, B. Viollet, and M. J. Birnbaum, “Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP,” Nature, vol. 494, no. 7436, pp. 256–260, 2013. View at Publisher · View at Google Scholar · View at Scopus
  186. R. A. Miller and M. J. Birnbaum, “An energetic tale of AMPK-independent effects of metformin,” Journal of Clinical Investigation, vol. 120, no. 7, pp. 2267–2270, 2010. View at Publisher · View at Google Scholar · View at Scopus
  187. B. Cool, B. Zinker, W. Chiou et al., “Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome,” Cell Metabolism, vol. 3, no. 6, pp. 403–416, 2006. View at Publisher · View at Google Scholar · View at Scopus
  188. D. Castaño, E. Larequi, I. Belza et al., “Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation,” Journal of Hepatology, vol. 60, no. 5, pp. 1017–1025, 2014. View at Publisher · View at Google Scholar · View at Scopus
  189. R. Bergeron, S. F. Previs, G. W. Cline et al., “Effect of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese zucker rats,” Diabetes, vol. 50, no. 5, pp. 1076–1082, 2001. View at Publisher · View at Google Scholar · View at Scopus
  190. D. J. Cuthbertson, J. A. Babraj, K. J. W. Mustard et al., “5-Aminoimidazole-4-carboxamide 1-β-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men,” Diabetes, vol. 56, no. 8, pp. 2078–2084, 2007. View at Publisher · View at Google Scholar · View at Scopus
  191. K.-G. Park, A.-K. Min, E. H. Koh et al., “Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways,” Hepatology, vol. 48, no. 5, pp. 1477–1486, 2008. View at Publisher · View at Google Scholar · View at Scopus
  192. S. Green and W. Wahli, “Peroxisome proliferator-activated receptors: finding the orphan a home,” Molecular and Cellular Endocrinology, vol. 100, no. 1-2, pp. 149–153, 1994. View at Publisher · View at Google Scholar · View at Scopus
  193. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Google Scholar · View at Scopus
  194. T. Hashimoto, W. S. Cook, C. Qi, A. V. Yeldandi, J. K. Reddy, and M. S. Rao, “Defect in peroxisome proliferator-activated receptor α-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting,” The Journal of Biological Chemistry, vol. 275, no. 37, pp. 28918–28928, 2000. View at Publisher · View at Google Scholar · View at Scopus
  195. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar · View at Scopus
  196. D. J. Mangelsdorf and R. M. Evans, “The RXR heterodimers and orphan receptors,” Cell, vol. 83, no. 6, pp. 841–850, 1995. View at Publisher · View at Google Scholar · View at Scopus
  197. M. T. Nakamura, B. E. Yudell, and J. J. Loor, “Regulation of energy metabolism by long-chain fatty acids,” Progress in Lipid Research, vol. 53, no. 1, pp. 124–144, 2014. View at Publisher · View at Google Scholar · View at Scopus
  198. E. Y. Jong, M. C. Kyung, H. B. Sei et al., “Reduced expression of peroxisome proliferator-activated receptor-β may have an important role in the development of non-alcoholic fatty liver disease,” Journal of Gastroenterology and Hepatology, vol. 19, no. 7, pp. 799–804, 2004. View at Publisher · View at Google Scholar · View at Scopus
  199. Y. Harano, K. Yasui, T. Toyama et al., “Fenofibrate, a peroxisome proliferator-activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver,” Liver International, vol. 26, no. 5, pp. 613–620, 2006. View at Publisher · View at Google Scholar · View at Scopus
  200. W.-N. Cong, R.-Y. Tao, J.-Y. Tian, G.-T. Liu, and F. Ye, “The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice,” Life Sciences, vol. 82, no. 19-20, pp. 983–990, 2008. View at Publisher · View at Google Scholar · View at Scopus
  201. V. G. Athyros, D. P. Mikhailidis, T. P. Didangelos et al., “Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study,” Current Medical Research and Opinion, vol. 22, no. 5, pp. 873–883, 2006. View at Publisher · View at Google Scholar · View at Scopus
  202. C. Fernández-Miranda, M. Pérez-Carreras, F. Colina, G. López-Alonso, C. Vargas, and J. A. Solís-Herruzo, “A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease,” Digestive and Liver Disease, vol. 40, no. 3, pp. 200–205, 2008. View at Publisher · View at Google Scholar · View at Scopus
  203. B. N. Finck, J. J. Lehman, T. C. Leone et al., “The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus,” Journal of Clinical Investigation, vol. 109, no. 1, pp. 121–130, 2002. View at Publisher · View at Google Scholar · View at Scopus
  204. C. Duval, M. Müller, and S. Kersten, “PPARα and dyslipidemia,” Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp. 961–971, 2007. View at Publisher · View at Google Scholar · View at Scopus
  205. S. Fatani, I. Itua, P. Clark, C. Wong, and E. K. Naderali, “The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage,” International Journal of General Medicine, vol. 4, pp. 211–219, 2011. View at Publisher · View at Google Scholar · View at Scopus
  206. S. Heikkinen, J. Auwerx, and C. A. Argmann, “PPARγ in human and mouse physiology,” Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1771, no. 8, pp. 999–1013, 2007. View at Publisher · View at Google Scholar · View at Scopus
  207. B. A. Neuschwander-Tetri, E. M. Brunt, K. R. Wehmeier, D. Oliver, and B. R. Bacon, “Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone,” Hepatology, vol. 38, no. 4, pp. 1008–1017, 2003. View at Publisher · View at Google Scholar · View at Scopus
  208. V. Ratziu, F. Charlotte, C. Bernhardt et al., “Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial,” Hepatology, vol. 51, no. 2, pp. 445–453, 2010. View at Publisher · View at Google Scholar · View at Scopus
  209. V. Ratziu, P. Giral, S. Jacqueminet et al., “Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial,” Gastroenterology, vol. 135, no. 1, pp. 100–110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  210. R. Belfort, S. A. Harrison, K. Brown et al., “A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 355, no. 22, pp. 2297–2307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  211. G. P. Aithal, J. A. Thomas, P. V. Kaye et al., “Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis,” Gastroenterology, vol. 135, no. 4, pp. 1176–1184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  212. A. M. Lincoff, K. Wolski, S. J. Nicholls, and S. E. Nissen, “Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials,” Journal of the American Medical Association, vol. 298, no. 10, pp. 1180–1188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  213. A. K. Saha, P. R. Avilucea, J.-M. Ye, M. M. Assifi, E. W. Kraegen, and N. B. Ruderman, “Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo,” Biochemical and Biophysical Research Communications, vol. 314, no. 2, pp. 580–585, 2004. View at Publisher · View at Google Scholar · View at Scopus
  214. L. G. D. Fryer, A. Parbu-Patel, and D. Carling, “The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways,” The Journal of Biological Chemistry, vol. 277, no. 28, pp. 25226–25232, 2002. View at Publisher · View at Google Scholar · View at Scopus
  215. N. K. LeBrasseur, M. Kelly, T.-S. Tsao et al., “Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 291, no. 1, pp. E175–E181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  216. A. R. Nawrocki, M. W. Rajala, E. Tomas et al., “Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferator-activated receptor γ agonists,” The Journal of Biological Chemistry, vol. 281, no. 5, pp. 2654–2660, 2006. View at Publisher · View at Google Scholar · View at Scopus
  217. N. Kubota, Y. Terauchi, T. Kubota et al., “Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways,” The Journal of Biological Chemistry, vol. 281, no. 13, pp. 8748–8755, 2006. View at Publisher · View at Google Scholar · View at Scopus
  218. U. Kintscher and R. E. Law, “PPARγ-mediated insulin sensitization: the importance of fat versus muscle,” The American Journal of Physiology—Endocrinology and Metabolism, vol. 288, no. 2, pp. E287–E291, 2005. View at Publisher · View at Google Scholar · View at Scopus
  219. A. V. W. Nunn, J. Bell, and P. Barter, “The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balance,” Nuclear Receptor, vol. 5, article 1, 2007. View at Publisher · View at Google Scholar · View at Scopus
  220. E. M. Burkart, N. Sambandam, X. Han et al., “Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart,” The Journal of Clinical Investigation, vol. 117, no. 12, pp. 3930–3939, 2007. View at Publisher · View at Google Scholar · View at Scopus
  221. B. Staels, A. Rubenstrunk, B. Noel et al., “Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis,” Hepatology, vol. 58, no. 6, pp. 1941–1952, 2013. View at Publisher · View at Google Scholar · View at Scopus
  222. T. Nagasawa, Y. Inada, S. Nakano et al., “Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet,” European Journal of Pharmacology, vol. 536, no. 1-2, pp. 182–191, 2006. View at Publisher · View at Google Scholar · View at Scopus
  223. Z. Wu, P. Puigserver, U. Andersson et al., “Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1,” Cell, vol. 98, no. 1, pp. 115–124, 1999. View at Publisher · View at Google Scholar · View at Scopus
  224. R. C. Scarpulla, “Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator,” Annals of the New York Academy of Sciences, vol. 1147, pp. 321–334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  225. S. Sookoian, M. S. Rosselli, C. Gemma et al., “Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter,” Hepatology, vol. 52, no. 6, pp. 1992–2000, 2010. View at Publisher · View at Google Scholar · View at Scopus
  226. S. Herzig, F. Long, U. S. Jhala et al., “CREB regulates hepatic gluconeogenesis through the coactivator PGC-1,” Nature, vol. 413, pp. 179–183, 2001. View at Google Scholar
  227. J. C. Yoon, P. Puigserver, G. Chen et al., “Control of hepatic gluconeogenesis through the transcriptional coaotivator PGC-1,” Nature, vol. 413, no. 6852, pp. 131–138, 2001. View at Publisher · View at Google Scholar · View at Scopus
  228. C. Kang, K. M. O'Moore, J. R. Dickman, and L. L. Ji, “Exercise activation of muscle peroxisome proliferator-activated receptor-γ coactivator-1α signaling is redox sensitive,” Free Radical Biology and Medicine, vol. 47, no. 10, pp. 1394–1400, 2009. View at Publisher · View at Google Scholar · View at Scopus
  229. S. Borniquel, I. Valle, S. Cadenas, S. Lamas, and M. Monsalve, “Nitric oxide regulates mitochondrial oxidative stress protection via the transcriptional coactivator PGC-1alpha,” The FASEB Journal, vol. 20, no. 11, pp. 1889–1891, 2006. View at Publisher · View at Google Scholar · View at Scopus
  230. N. Kumashiro, Y. Tamura, T. Uchida et al., “Impact of oxidative stress and peroxisome proliferator-activated receptor γ coactivator-1α in hepatic insulin resistance,” Diabetes, vol. 57, no. 8, pp. 2083–2091, 2008. View at Publisher · View at Google Scholar · View at Scopus
  231. C. Cantó and J. Auwerx, “AMP-activated protein kinase and its downstream transcriptional pathways,” Cellular and Molecular Life Sciences, vol. 67, no. 20, pp. 3407–3423, 2010. View at Publisher · View at Google Scholar · View at Scopus
  232. R. A. Screaton, M. D. Conkright, Y. Katoh et al., “The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector,” Cell, vol. 119, no. 1, pp. 61–74, 2004. View at Publisher · View at Google Scholar · View at Scopus
  233. S.-H. Koo, L. Flechner, L. Qi et al., “The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism,” Nature, vol. 437, no. 7062, pp. 1109–1114, 2005. View at Publisher · View at Google Scholar · View at Scopus
  234. R. K. Gupta and K. H. Kaestner, “HNF-4α: from MODY to late-onset type 2 diabetes,” Trends in Molecular Medicine, vol. 10, no. 11, pp. 521–524, 2004. View at Publisher · View at Google Scholar · View at Scopus
  235. Y. H. Hong, U. S. Varanasi, W. Yang, and T. Leff, “AMP-activated protein kinase regulates HNF4alpha transcriptional activity by inhibiting dimer formation and decreasing protein stability,” The Journal of Biological Chemistry, vol. 278, no. 30, pp. 495–501, 2003. View at Google Scholar
  236. I. Leclerc, C. Lenzner, L. Gourdon, S. Vaulont, A. Kahn, and B. Viollet, “Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase,” Diabetes, vol. 50, no. 7, pp. 1515–1521, 2001. View at Publisher · View at Google Scholar · View at Scopus
  237. S.-M. Aatsinki, M. Buler, H. Salomäki, M. Koulu, P. Pavek, and J. Hakkola, “Metformin induces PGC-1α expression and selectively affects hepatic PGC-1α functions,” British Journal of Pharmacology, vol. 171, no. 9, pp. 2351–2363, 2014. View at Publisher · View at Google Scholar · View at Scopus
  238. Y. D. Kim, K.-G. Park, Y.-S. Lee et al., “Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP,” Diabetes, vol. 57, no. 2, pp. 306–314, 2008. View at Publisher · View at Google Scholar · View at Scopus
  239. T. T. Lu, J. J. Repa, and D. J. Mangelsdorf, “Orphan nuclear receptors as eLiXiRs and FiXeRs of sterol metabolism,” The Journal of Biological Chemistry, vol. 276, no. 41, pp. 37735–37738, 2001. View at Publisher · View at Google Scholar · View at Scopus
  240. T. Yoshikawa, H. Shimano, M. Amemiya-Kudo et al., “Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter,” Molecular and Cellular Biology, vol. 21, no. 9, pp. 2991–3000, 2001. View at Publisher · View at Google Scholar · View at Scopus
  241. S. B. Joseph, B. A. Laffitte, P. H. Patel et al., “Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors,” The Journal of Biological Chemistry, vol. 277, no. 13, pp. 11019–11025, 2002. View at Publisher · View at Google Scholar · View at Scopus
  242. N. Higuchi, M. Kato, Y. Shundo et al., “Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease,” Hepatology Research, vol. 38, no. 11, pp. 1122–1129, 2008. View at Publisher · View at Google Scholar · View at Scopus
  243. R. C. Murphy and K. M. Johnson, “Cholesterol, reactive oxygen species, and the formation of biologically active mediators,” The Journal of Biological Chemistry, vol. 283, no. 23, pp. 15521–15525, 2008. View at Publisher · View at Google Scholar · View at Scopus
  244. T. Ikegami, H. Hyogo, A. Honda et al., “Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease,” Journal of Gastroenterology, vol. 47, no. 11, pp. 1257–1266, 2012. View at Publisher · View at Google Scholar · View at Scopus
  245. V. M. Olkkonen and R. Hynynen, “Interactions of oxysterols with membranes and proteins,” Molecular Aspects of Medicine, vol. 30, no. 3, pp. 123–133, 2009. View at Publisher · View at Google Scholar · View at Scopus
  246. H. Y. Kay, W. D. Kim, S. J. Hwang et al., “Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding,” Antioxidants & Redox Signaling, vol. 15, no. 8, pp. 2135–2146, 2011. View at Publisher · View at Google Scholar · View at Scopus
  247. Y. W. Kim, Y. M. Kim, Y. M. Yang et al., “Inhibition of LXRalpha-dependent steatosis and oxidative injury by liquiritigenin, a licorice flavonoid, as mediated with Nrf2 activation,” Antioxidants and Redox Signaling, vol. 14, no. 5, pp. 733–745, 2011. View at Publisher · View at Google Scholar · View at Scopus
  248. Y. Li, K. Jadhav, and Y. Zhang, “Bile acid receptors in non-alcoholic fatty liver disease,” Biochemical Pharmacology, vol. 86, no. 11, pp. 1517–1524, 2013. View at Publisher · View at Google Scholar · View at Scopus
  249. D. J. Parks, S. G. Blanchard, R. K. Bledsoe et al., “Bile acids: natural ligands for an orphan nuclear receptor,” Science, vol. 284, no. 5418, pp. 1365–1368, 1999. View at Publisher · View at Google Scholar · View at Scopus
  250. P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels, “Role of bile acids and bile acid receptors in metabolic regulation,” Physiological Reviews, vol. 89, no. 1, pp. 147–191, 2009. View at Publisher · View at Google Scholar · View at Scopus
  251. F. Y. Lee, H. Lee, M. L. Hubbert, P. A. Edwards, and Y. Zhang, “FXR, a multipurpose nuclear receptor,” Trends in Biochemical Sciences, vol. 31, no. 10, pp. 572–580, 2006. View at Publisher · View at Google Scholar · View at Scopus
  252. E. Ip, G. C. Farrell, G. Robertson, P. Hall, R. Kirsch, and I. Leclercq, “Central role of PPARα-dependent hepatic lipid turnover in dietary steatohepatitis in mice,” Hepatology, vol. 38, no. 1, pp. 123–132, 2003. View at Publisher · View at Google Scholar · View at Scopus
  253. Z.-X. Yang, W. Shen, and H. Sun, “Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease,” Hepatology International, vol. 4, no. 4, pp. 741–748, 2010. View at Publisher · View at Google Scholar · View at Scopus
  254. Y. Zhang, L. W. Castellani, C. J. Sinal, F. J. Gonzalez, and P. A. Edwards, “Peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) regulates triglyceride metabolism by activation of the nuclear receptor FXR,” Genes and Development, vol. 18, no. 2, pp. 157–169, 2004. View at Publisher · View at Google Scholar · View at Scopus
  255. K. Ma, P. K. Saha, L. Chan, and D. D. Moore, “Farnesoid X receptor is essential for normal glucose homeostasis,” The Journal of Clinical Investigation, vol. 116, no. 4, pp. 1102–1109, 2006. View at Publisher · View at Google Scholar · View at Scopus
  256. Y.-D. Wang, W.-D. Chen, M. Wang, D. Yu, B. M. Forman, and W. Huang, “Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response,” Hepatology, vol. 48, no. 5, pp. 1632–1643, 2008. View at Publisher · View at Google Scholar · View at Scopus
  257. S. Fiorucci, E. Antonelli, G. Rizzo et al., “The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis,” Gastroenterology, vol. 127, no. 5, pp. 1497–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  258. S. Fiorucci, G. Rizzo, E. Antonelli et al., “A farnesoid X receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis,” The Journal of Pharmacology and Experimental Therapeutics, vol. 314, no. 2, pp. 584–595, 2005. View at Publisher · View at Google Scholar · View at Scopus
  259. A. Baghdasaryan, T. Claudel, J. Gumhold et al., “Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2−/− (Abcb4−/−) mouse cholangiopathy model by promoting biliary HCO3− output,” Hepatology, vol. 54, no. 4, pp. 1303–1312, 2011. View at Publisher · View at Google Scholar · View at Scopus
  260. S. Krähenbühl, C. Talos, S. Fischer, and J. Reichen, “Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria,” Hepatology, vol. 19, no. 2, pp. 471–479, 1994. View at Publisher · View at Google Scholar · View at Scopus
  261. B. Blumberg, W. Sabbagh Jr., H. Juguilon et al., “SXR, a novel steroid and xenobiotic-sensing nuclear receptor,” Genes and Development, vol. 12, no. 20, pp. 3195–3205, 1998. View at Publisher · View at Google Scholar · View at Scopus
  262. A. Moreau, C. Téruel, M. Beylot et al., “A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte,” Hepatology, vol. 49, no. 6, pp. 2068–2079, 2009. View at Publisher · View at Google Scholar · View at Scopus
  263. K. Nakamura, R. Moore, M. Negishi, and T. Sueyoshi, “Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver,” The Journal of Biological Chemistry, vol. 282, no. 13, pp. 9768–9776, 2007. View at Publisher · View at Google Scholar · View at Scopus
  264. S. Bhalla, C. Ozalp, S. Fang, L. Xiang, and J. K. Kemper, “Ligand-activated pregnane X receptor interferes with HNF-4 signaling by targeting a common coactivator PGC-1α. Functional implications in hepatic cholesterol and glucose metabolism,” The Journal of Biological Chemistry, vol. 279, no. 43, pp. 45139–45147, 2004. View at Publisher · View at Google Scholar · View at Scopus
  265. L. Valenti, R. Rametta, P. Dongiovanni et al., “Increased expression and activity of the transcription factor FOXO1 in nonalcoholic steatohepatitis,” Diabetes, vol. 57, no. 5, pp. 1355–1362, 2008. View at Publisher · View at Google Scholar · View at Scopus
  266. J. He, J. Gao, M. Xu et al., “PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice,” Diabetes, vol. 62, no. 6, pp. 1876–1887, 2013. View at Publisher · View at Google Scholar · View at Scopus
  267. S. Mani, W. Dou, and M. R. Redinbo, “PXR antagonists and implication in drug metabolism,” Drug Metabolism Reviews, vol. 45, no. 1, pp. 60–72, 2013. View at Publisher · View at Google Scholar · View at Scopus
  268. S. Ekins, V. Kholodovych, N. Ai et al., “Computational discovery of novel low micromolar human pregnane X receptor antagonists,” Molecular Pharmacology, vol. 74, no. 3, pp. 662–672, 2008. View at Publisher · View at Google Scholar · View at Scopus
  269. A. Biswas, S. Mani, M. R. Redinbo, M. D. Krasowski, H. Li, and S. Ekins, “Elucidating the “Jekyll and Hyde” nature of PXR: the case for discovering antagonists or allosteric antagonists,” Pharmaceutical Research, vol. 26, no. 8, pp. 1807–1815, 2009. View at Publisher · View at Google Scholar · View at Scopus
  270. M. Kohjima, N. Higuchi, M. Kato et al., “SREBP-1c, regulated by the insulin and AMPK signaling pathways, plays a role in nonalcoholic fatty liver disease,” International Journal of Molecular Medicine, vol. 21, no. 4, pp. 507–511, 2008. View at Google Scholar · View at Scopus
  271. E. Furuta, S. K. Pai, R. Zhan et al., “Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1,” Cancer Research, vol. 68, no. 4, pp. 1003–1011, 2008. View at Publisher · View at Google Scholar · View at Scopus
  272. M. Sekiya, A. Hiraishi, M. Touyama, and K. Sakamoto, “Oxidative stress induced lipid accumulation via SREBP1c activation in HepG2 cells,” Biochemical and Biophysical Research Communications, vol. 375, no. 4, pp. 602–607, 2008. View at Publisher · View at Google Scholar · View at Scopus
  273. K. Cao, J. Xu, X. Zou et al., “Hydroxytyrosol prevents diet-induced metabolic syndrome and attenuates mitochondrial abnormalities in obese mice,” Free Radical Biology & Medicine, vol. 67, pp. 396–407, 2014. View at Publisher · View at Google Scholar · View at Scopus
  274. M. Ono, M. Ogasawara, A. Hirose et al., “Bofutsushosan, a Japanese herbal (Kampo) medicine, attenuates progression of nonalcoholic steatohepatitis in mice,” Journal of Gastroenterology, vol. 49, no. 6, pp. 1065–1073, 2014. View at Publisher · View at Google Scholar · View at Scopus
  275. M. Endo, T. Masaki, M. Seike, and H. Yoshimatsu, “TNF-α induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c),” Experimental Biology and Medicine, vol. 232, no. 5, pp. 614–621, 2007. View at Google Scholar · View at Scopus
  276. A. Woods, D. Azzout-Marniche, M. Foretz et al., “Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase,” Molecular and Cellular Biology, vol. 20, no. 18, pp. 6704–6711, 2000. View at Publisher · View at Google Scholar · View at Scopus